Aarti Pharmalabs has announced a board meeting to be held on February 09, 2026. The primary agenda is to review and approve the unaudited financial results for the quarter ended December 31, 2025 (Q3). The board will also consider the declaration of an interim dividend, if any. Trading window, already closed since January 01, 2026, will remain closed until February 11, 2026.
Board Meeting Announcement
Aarti Pharmalabs has scheduled a meeting of its Board of Directors to be held on Monday, February 09, 2026. The meeting will primarily focus on the following key items:
Key Agenda Items
The board will review and approve the unaudited financial results of the company for the quarter ending December 31, 2025 (Q3). These results will be evaluated by the Audit Committee before being presented to the board.
The board will also consider the declaration of an interim dividend, based on the company’s financial performance and outlook for the financial year 2025-26. The decision regarding the dividend will be based on financial parameters and strategic considerations.
Trading Window Closure
As per the company’s code for the prevention of insider trading, the trading window for transactions in the company’s securities has been closed since January 01, 2026. This closure will remain in effect until February 11, 2026, to allow for the announcement of the aforementioned results. This measure ensures fair and transparent trading practices related to the company’s shares.
Source: BSE
